pantoprazole has been researched along with Zollinger-Ellison Syndrome in 17 studies
Pantoprazole: 2-pyridinylmethylsulfinylbenzimidazole proton pump inhibitor that is used in the treatment of GASTROESOPHAGEAL REFLUX and PEPTIC ULCER.
pantoprazole : A member of the class of benzimidazoles that is 1H-benzimidazole substituted by a difluoromethoxy group at position 5 and a [(3,4-dimethoxypyridin-2-yl)methyl]sulfinyl group at position 2.
Zollinger-Ellison Syndrome: A syndrome that is characterized by the triad of severe PEPTIC ULCER, hypersecretion of GASTRIC ACID, and GASTRIN-producing tumors of the PANCREAS or other tissue (GASTRINOMA). This syndrome may be sporadic or be associated with MULTIPLE ENDOCRINE NEOPLASIA TYPE 1.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The safety and efficacy data for short-term (6-month) treatment of Zollinger-Ellison syndrome and idiopathic hypersecretion with oral pantoprazole were previously published." | 9.12 | Three-year oral pantoprazole administration is effective for patients with Zollinger-Ellison syndrome and other hypersecretory conditions. ( Chey, W; Comer, GM; Cryer, B; Forsmark, CE; Metz, DC; Pisegna, JR; Soffer, E, 2006) |
| "In this open prospective study, the efficacy of pantoprazole in reducing gastric acid secretion in Zollinger-Ellison syndrome patients was compared to that obtained previously with other proton pump inhibitors." | 9.10 | Effect of pantoprazole versus other proton pump inhibitors on 24-hour intragastric pH and basal acid output in Zollinger-Ellison syndrome. ( Mignon, M; Ramdani, A; Samoyeau, R, 2002) |
| " pantoprazole therapy at a dose of 80-240 mg/day in divided doses was both effective and generally well tolerated for patients with Zollinger-Ellison syndrome and idiopathic hypersecretion." | 7.72 | Maintenance oral pantoprazole therapy is effective for patients with Zollinger-Ellison syndrome and idiopathic hypersecretion. ( Bochenek, W; Chey, W; Cryer, B; Forsmark, CE; Metz, DC; Pisegna, JR; Soffer, E, 2003) |
| "Pantoprazole was administered at an initial dose of 80 mg daily for seven days before basal acid output (BAO) was measured at 08:00, ie, 1 h before the next dose of pantoprazole was normally ingested." | 5.31 | Oral pantoprazole for acid suppression in the treatment of patients with Zollinger-Ellison syndrome. ( Désir, B; Poitras, P, 2001) |
| "pantoprazole was evaluated in 14 ZES patients." | 5.31 | Replacement of oral proton pump inhibitors with intravenous pantoprazole to effectively control gastric acid hypersecretion in patients with Zollinger-Ellison syndrome. ( Bochenek, W; Forsmark, C; Lew, EA; Metz, DC; Pisegna, JR; Soffer, EF; Starr, JA, 2001) |
| "The safety and efficacy data for short-term (6-month) treatment of Zollinger-Ellison syndrome and idiopathic hypersecretion with oral pantoprazole were previously published." | 5.12 | Three-year oral pantoprazole administration is effective for patients with Zollinger-Ellison syndrome and other hypersecretory conditions. ( Chey, W; Comer, GM; Cryer, B; Forsmark, CE; Metz, DC; Pisegna, JR; Soffer, E, 2006) |
| "In this open prospective study, the efficacy of pantoprazole in reducing gastric acid secretion in Zollinger-Ellison syndrome patients was compared to that obtained previously with other proton pump inhibitors." | 5.10 | Effect of pantoprazole versus other proton pump inhibitors on 24-hour intragastric pH and basal acid output in Zollinger-Ellison syndrome. ( Mignon, M; Ramdani, A; Samoyeau, R, 2002) |
| " Pentagastrin was infused continuously in healthy subjects as a model for patients with Zollinger-Ellison syndrome." | 5.09 | Inhibition of pentagastrin-induced gastric acid secretion by intravenous pantoprazole: a dose-response study. ( Martin, P; McKeand, W; Ohning, G; Paul, J; Pisegna, JR; Walsh, JH, 1999) |
| " pantoprazole therapy at a dose of 80-240 mg/day in divided doses was both effective and generally well tolerated for patients with Zollinger-Ellison syndrome and idiopathic hypersecretion." | 3.72 | Maintenance oral pantoprazole therapy is effective for patients with Zollinger-Ellison syndrome and idiopathic hypersecretion. ( Bochenek, W; Chey, W; Cryer, B; Forsmark, CE; Metz, DC; Pisegna, JR; Soffer, E, 2003) |
| "Pantoprazole (Protonix) is an irreversible proton pump inhibitor (PPI) that reduces gastric acid secretion." | 2.42 | Pantoprazole: an update of its pharmacological properties and therapeutic use in the management of acid-related disorders. ( Cheer, SM; Faulds, D; Lamb, HM; Prakash, A, 2003) |
| " Intravenous pantoprazole is especially distinguished in its lack of clinically relevant drug interactions, and it requires no dosage adjustment for patients with renal insufficiency or with mild to moderate hepatic dysfunction." | 2.41 | Potential uses of intravenous proton pump inhibitors to control gastric acid secretion. ( Metz, DC, 2000) |
| " Another advantage over the histamine 2 receptor antagonists is that pantoprazole does not require dosage adjustment in patients with renal impairment." | 2.41 | Intravenous pantoprazole: a new tool for acutely ill patients who require acid suppression. ( Trépanier, EF, 2000) |
| "Pantoprazole was administered at an initial dose of 80 mg daily for seven days before basal acid output (BAO) was measured at 08:00, ie, 1 h before the next dose of pantoprazole was normally ingested." | 1.31 | Oral pantoprazole for acid suppression in the treatment of patients with Zollinger-Ellison syndrome. ( Désir, B; Poitras, P, 2001) |
| "pantoprazole was evaluated in 14 ZES patients." | 1.31 | Replacement of oral proton pump inhibitors with intravenous pantoprazole to effectively control gastric acid hypersecretion in patients with Zollinger-Ellison syndrome. ( Bochenek, W; Forsmark, C; Lew, EA; Metz, DC; Pisegna, JR; Soffer, EF; Starr, JA, 2001) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (11.76) | 18.2507 |
| 2000's | 13 (76.47) | 29.6817 |
| 2010's | 1 (5.88) | 24.3611 |
| 2020's | 1 (5.88) | 2.80 |
| Authors | Studies |
|---|---|
| Reisinger, AC | 1 |
| Eller, P | 1 |
| Schilcher, G | 1 |
| Eisner, F | 1 |
| Kreuzer, P | 1 |
| Hackl, G | 1 |
| Spindelböck, W | 1 |
| Plank, J | 1 |
| Kump, P | 1 |
| Ebbelaar, CF | 1 |
| Lammers, HA | 1 |
| Schobben, AF | 1 |
| Cheer, SM | 1 |
| Prakash, A | 1 |
| Faulds, D | 1 |
| Lamb, HM | 1 |
| Leitner, A | 1 |
| Zöllner, P | 1 |
| Metz, DC | 5 |
| Soffer, E | 2 |
| Forsmark, CE | 2 |
| Cryer, B | 2 |
| Chey, W | 2 |
| Bochenek, W | 3 |
| Pisegna, JR | 6 |
| Comer, GM | 1 |
| Dítĕ, P | 1 |
| Prásek, J | 1 |
| Martin, P | 1 |
| McKeand, W | 1 |
| Ohning, G | 1 |
| Walsh, JH | 2 |
| Paul, J | 1 |
| Lew, EA | 2 |
| Starr, JA | 2 |
| Soffer, EF | 2 |
| Forsmark, C | 2 |
| Modlin, IM | 1 |
| Beg, M | 1 |
| Trépanier, EF | 1 |
| Désir, B | 1 |
| Poitras, P | 1 |
| Ramdani, A | 1 |
| Mignon, M | 1 |
| Samoyeau, R | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Comparison of Intravenous Pantoprazole and Famotidine for Stress Ulcer Prophylaxis in Patients After Major Abdominal Surgery[NCT00839488] | Phase 4 | 6 participants (Actual) | Interventional | 2008-04-30 | Terminated (stopped due to the chief of GS left the hopsital and the successor did't want to keep on this study) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
5 reviews available for pantoprazole and Zollinger-Ellison Syndrome
| Article | Year |
|---|---|
Pantoprazole: an update of its pharmacological properties and therapeutic use in the management of acid-related disorders.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; | 2003 |
Treating patients with acute gastrointestinal bleeding or rebleeding.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Benzimidazoles; Clinical Trials a | 2003 |
[Proton pump blockers and their significance in gastroenterology].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Esophagitis, Peptic; Gas | 1995 |
Potential uses of intravenous proton pump inhibitors to control gastric acid secretion.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Gastric Acid; Gastric Ac | 2000 |
Intravenous pantoprazole: a new tool for acutely ill patients who require acid suppression.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Benzimidazoles; Enzyme Inhibitors; Esophagitis, Peptic; Gas | 2000 |
4 trials available for pantoprazole and Zollinger-Ellison Syndrome
| Article | Year |
|---|---|
Three-year oral pantoprazole administration is effective for patients with Zollinger-Ellison syndrome and other hypersecretory conditions.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Aged; Anti-Ulcer Agents; Benzimidazol | 2006 |
Inhibition of pentagastrin-induced gastric acid secretion by intravenous pantoprazole: a dose-response study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Anti-Ulcer Agents; Benzimidazoles; Dose- | 1999 |
Intravenous pantoprazole rapidly controls gastric acid hypersecretion in patients with Zollinger-Ellison syndrome.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Ulcer Agents; Benzimidazoles; Female; Gas | 2000 |
Effect of pantoprazole versus other proton pump inhibitors on 24-hour intragastric pH and basal acid output in Zollinger-Ellison syndrome.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Female; Gastric Acid; Ga | 2002 |
8 other studies available for pantoprazole and Zollinger-Ellison Syndrome
| Article | Year |
|---|---|
Manifestation of Zollinger-Ellison Syndrome With Hypovolemic Shock.
Topics: Humans; Male; Middle Aged; Pantoprazole; Proton Pump Inhibitors; Shock; Zollinger-Ellison Syndrome | 2020 |
[Switching to a generic drugA blessing or a curse?].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Drugs, Generic; Esomeprazole; Humans; Pa | 2016 |
[Visual documentation of the stability of intravenous solutions of omeprazole (Losec) and pantoprazole (Pantoloc)].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Drug Stability; Drug Sto | 2002 |
Maintenance oral pantoprazole therapy is effective for patients with Zollinger-Ellison syndrome and idiopathic hypersecretion.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Benzimidazoles; Dose-Response Relatio | 2003 |
Oral pantoprazole for acid suppression in the treatment of patients with Zollinger-Ellison syndrome.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Anti-Ulcer Agents; Benzimidazoles; Female; Gastric Ac | 2001 |
Replacement of oral proton pump inhibitors with intravenous pantoprazole to effectively control gastric acid hypersecretion in patients with Zollinger-Ellison syndrome.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Adult; Aged; Benzimidazoles; Dose-Res | 2001 |
Protonix. First i.v. proton pump inhibitor approved.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Clinical Trials as Topic | 2002 |
Pantoprazole IV (Protonix IV).
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Benzimidazoles; Clinical Trials as Topic; Drug Approval; Fe | 2002 |